Loomis Sayles & CO L P Akero Therapeutics, Inc. Transaction History
Loomis Sayles & CO L P
- $69.2 Billion
- Q1 2025
A detailed history of Loomis Sayles & CO L P transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 488,938 shares of AKRO stock, worth $23.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
488,938Holding current value
$23.6 Million% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$358 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$341 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$286 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$269 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$252 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.24B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...